Published in Gene Therapy Weekly, December 21st, 1998
The chemotherapeutic effectiveness of cytosine nucleoside analogues used in cancer therapy is limited by their dose-dependent myelosuppression.
One approach to overcome this problem would be to insert the drug-resistant gene cytidine deaminase (CD), into normal hematopoietic cells. CD catalyzes the deamination and pharmacological inactivation of cytosine nucleoside analogues, such as cytosine arabinoside (Ara-C), noted N. Eliopoulos and colleagues ("Retroviral Transfer and Long-Term Expression of Human Cytidine Deaminase cDNA in Hematopoietic Cells following...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly
Source: Gene Therapy Weekly (1998-12-21)
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.